Sage Journals: Discover world-class research

Abstract

Carfilzomib is a proteasome inhibitor and immunomodulator used to treat patients with multiple myeloma who have disease progression refractory to bortezomib. The difference in agents is that carfilzomib is an irreversible inhibitor of 20 s proteasome. The most common side effects of carfilzomib are fatigue, nausea, diarrhea, anemia, thrombocytopenia, dyspnea, and pyrexia. Less frequent side effects include cardiac manifestations for which we will explore with more detail. In this case report, we describe a 70-year-old female with multiple myeloma presenting to the emergency department with complaint of dyspnea. Patient was discovered to be in heart failure with atrioventricular block necessitating placement of a pacemaker.

Keywords

Carfilzomib heart block heart failure emergency department oncologic emergency

Get full access to this article

View all access options for this article.

References

Tamargo

Ricardo

Eva

. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 1–24.

Shah

Anju

. Advanced heart failure due to cancer therapy. Curr Cardiol Rep 2015; 17: 1–9.

Carver

Chaitali

. Cardiovascular toxicity of antitumor drugs: dimension of the problem in adult settings. Cardiotox Non Cardiovasc Drugs 2010, pp. 127–199.

Siegel

Martin

Wang

. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817–2825.

Bringhen

Petrucci

Larocca

. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014; 124: 63–69.

Lendvai

Hilden

Devlin

. A phase 2 single-center study of carfilzomib 56 mg/m 2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 2014; 124: 899–906.

Herndon

Deisseroth

Kaminskas

. US food and drug administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 4559–4563.

Jesús

FSM.

. Quantifying the risk of heart failure associated with proteasome inhibition: a retrospective analysis of heart failure reported in phase 2 and phase 3 studies of bortezomib (Btz) in multiple myeloma (MM). Blood 2013; 122. 3187–3187.

Badros

Vij

Martin

. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27: 1707–1714.

10.

Scarabelli

Mara

Carol

C-S

. Cardiovascular toxicity of carfilzomib on vascular tone, vascular reactivity and endothelial function. Circulation 2014; 130(Suppl 2): A12193–A12193.

11.

Chari

Daher

. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer 2014; 14: 915–915.

12.

Harvey

. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014; 6: 87–87.

13.

Grandin

. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Cardiac Fail 2014; 21(2): 138–144.

14.

Micromedex

. Micromedex healthcare series. Carfilzomib 2015.

15.

Judith

. Tintinalli's emergency medicine: a comprehensive study guide 20117th ed. Part 7. Section 6. New York, NY: McGraw-Hill.

16.

Drews

Heinrich

. Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. Antioxid Redox Signal 2014; 21: 2322–2343.

17.

Shah D, et al. Multiple myeloma. Medscape, 19 May 2015. Web.

Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients

Abstract

Keywords

Get full access to this article

References